GlassScriptPhysician profile
Monica K Davis
NPI 1548700412
$5,875.61
in general payments reported to CMS, 2019-2025
12 companies · $2,144 in 2025
The $2,144 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,458 · 2022: $177 · 2023: $433 · 2024: $664 · 2025: $2,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,879 · Travel and Lodging: $1,112 · Consulting Fee: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,879.08 |
| Travel and Lodging | $1,112.21 |
| Consulting Fee | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hollister Incorporated | $2,515.57 | 2021-2025 | New Image, Hollister, Adapt Ceraring |
| Convatec INC. | $1,655.90 | 2024-2025 | |
| Kerecis Limited | $569.68 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Kci USA, INC. | $415.49 | 2023 | 3m Cavilon, Promogran Prisma, V.A.C. Granufoam |
| Organogenesis INC. | $278.45 | 2024-2025 | Cygnus Matrix |
| Medtronic, INC. | $208.19 | 2021-2023 | Interstim |
| Smith+Nephew, INC. | $97.29 | 2022-2024 | Collagenase Santyl |
| Solventum Corporation | $54.00 | 2024 | V.A.C. Veraflo, V.A.C. Veraflo Cleanse Choice, V.A.C. Dermatac |
| Abbvie INC. | $33.05 | 2025 | |
| Teleflex LLC | $19.91 | 2021 | |
| Mimedx Group, INC. | $14.98 | 2024 | |
| Reprise Biomedical, INC. | $13.10 | 2025 | Miro3d |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.